We serve Chemical Name:ethyl 1,3-dithiolane-2-carboxylate CAS:20461-99-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:ethyl 1,3-dithiolane-2-carboxylate
CAS.NO:20461-99-8
Synonyms:2-Carboethoxydithiolane;1,3-Dithiolane-2-carboxylic Acid Ethyl Ester;Ethyl-1,3-dithiolan-2-carboxylat;Ethyl 1,3-dithiolane-2-carboxylate;ethyl dithiolane-2-carboxylate;2-ethoxycarbonyl-1,3-dithiolane;ethyl 2,2-(1,3-dithiolane-2-yl)acetate;MFCD00005411;EINECS 243-837-9
Molecular Formula:C6H10O2S2
Molecular Weight:178.27200
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:85 °C0.1 mm Hg(lit.)
Density:1.249 g/mL at 25 °C(lit.)
Index of Refraction:n20/D 1.539(lit.)
PSA:76.90000
Exact Mass:178.01200
LogP:1.35560
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:3334
Packing Group:
Contact us for information like 2-Carboethoxydithiolane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 243-837-9 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl dithiolane-2-carboxylate Use and application,Ethyl 1,3-dithiolane-2-carboxylate technical grade,usp/ep/jp grade.
Related News: SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 1-(5-((4-(4-(piperazin-1-ylsulfonyl)phenyl)pyrimidin-2-yl)amino)benzofuran-2-yl)ethan-1-one manufacturers Aduhelm was approved by the Food and Drug Administration on June 7. The drug, scientifically known as aducanumab, offers new hope to friends and families of patients living with the disease and is expected to generate billions of dollars in revenue for the company. 4-Pyridinecarboxylic acid, 2,6-bis[(trimethylsilyl)ethynyl]-, methyl ester suppliers Over the duration of this study, investigators observed a 4.2% reduction in annualised absolute risk of cardiovascular death or heart failure hospitalisations compared to placebo. cis-3-hydroxythiacyclohexane S-oxide vendor & factory.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 1-(5-((4-(4-(piperazin-1-ylsulfonyl)phenyl)pyrimidin-2-yl)amino)benzofuran-2-yl)ethan-1-one manufacturers Aduhelm was approved by the Food and Drug Administration on June 7. The drug, scientifically known as aducanumab, offers new hope to friends and families of patients living with the disease and is expected to generate billions of dollars in revenue for the company. 4-Pyridinecarboxylic acid, 2,6-bis[(trimethylsilyl)ethynyl]-, methyl ester suppliers Over the duration of this study, investigators observed a 4.2% reduction in annualised absolute risk of cardiovascular death or heart failure hospitalisations compared to placebo. cis-3-hydroxythiacyclohexane S-oxide vendor & factory.
